ACAD
NASDAQACADIA Pharmaceuticals Inc.
Website
News25/Ratings12
News · 26 weeks44-74%
2025-10-262026-04-19
Mix3190d
- Insider16(52%)
- Other7(23%)
- Analyst3(10%)
- Earnings2(6%)
- SEC Filings2(6%)
- Leadership1(3%)
Latest news
25 items- PRAcadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual MeetingAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL. The Company will present real-world data from a sub-group analysis of the ongoing, Phase 4, prospective, observational, open-label LOTUS study evaluating the benefits and tolerability of DAYBUE® (trofinetide) in adults with Rett syndrome in routine clinical practice. In support of NUPLAZID® (pimavanserin) in Parkinson's disease psychosis (PDP), Acadia will present exploratory analyses evaluating heterogeneity in treatment response trajectories
- PRAcadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in numb
- INSIDERSEC Form 4 filed by Schneyer Mark C.4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by Kihara James4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- PRAcadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome-- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for Rett syndrome and highlights the importance of flexible, patient-centered treatment approaches Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE
- INSIDERSEC Form 4 filed by Thompson Elizabeth H.Z.4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by Rhodes Jennifer J4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by Owen Adams Catherine4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by Schneyer Mark C.4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by Kihara James4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ACADIA Pharmaceuticals Inc.SCHEDULE 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
- ANALYSTACADIA Pharmaceuticals upgraded by BofA Securities with a new price targetBofA Securities upgraded ACADIA Pharmaceuticals from Neutral to Buy and set a new price target of $29.00
- INSIDERSEC Form 4 filed by Poole Jonathan4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 3 filed by new insider Poole Jonathan3 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- PRAcadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS ForumAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and onl
- INSIDERSEC Form 4 filed by ACADIA Pharmaceuticals Inc.4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by ACADIA Pharmaceuticals Inc.4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by EVP, CHIEF LEGAL OFFICER, SEC Rhodes Jennifer J4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by ACADIA Pharmaceuticals Inc.4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Chief Commercial Officer Garner Thomas4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- INSIDERSEC Form 4 filed by PRINCIPAL ACCOUNTING OFFICER Kihara James4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- SECACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
- PRAcadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of DirectorsAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert
- PRAcadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett SyndromeAcadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally adopted a negative opinion regarding the Marketing Authorization Application for trofinetide for the treatment of Rett syndrome in patients two years of age and older. Acadia has reviewed the CHMP grounds for refusal in detail and intends to request a re-examination of the opinion. While the pivotal LAVENDERTM trial successfully met its co-primary and key secondary endpoints, the CHMP issued a refusal based on perceived deficits including: the treatment effect observed with trofinetide after 12
- SECACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)